Abemaciclib, a selective CDK4/6 inhibitor, reduces tumor cell growth primarily through an Rb gene-dependent mechanism, and clinical trials of abemaciclib in combination with pembrolizumab for TNBC are ongoing [199]. The gene discussed is RB1; the disease is neoplasm.